AMY PAUL: Open Payments
NPI 1265002018 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,271 in 237 payments from 19 companies in 2025. Trend: 2023 $2,586 · 2024 $2,201 · 2025 $4,271
Food & beverage: $4,271
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 52 | $734 |
| Axsome Therapeutics, Inc. | 33 | $733 |
| Otsuka America Pharmaceutical, Inc. | 17 | $326 |
| ABBVIE INC. | 21 | $301 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $294 |
| Janssen Pharmaceuticals, Inc | 11 | $255 |
| Alkermes, Inc. | 16 | $228 |
| Lundbeck LLC | 12 | $208 |
| Teva Pharmaceuticals USA, Inc. | 9 | $206 |
| Corium, LLC | 10 | $175 |
Products named: INGREZZA, Auvelity, REXULTI, VRAYLAR, CAPLYTA, SPRAVATO, ARISTADA, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
